Palbociclib for Prostate Cancer

There is little evidence for viruses or bacteria to cause prostate cancer. Tobacco smoking is the strongest known lifestyle risk factor for the disease. However, there is some evidence that prostate cancer may be prevented by having regular exercise, reducing alcohol consumption, and avoiding diethylene glycol in antifreeze. It may be caused by prostatic inflammation.\n

The treatments for prostate cancer and treatment effects on the symptoms of fatigue and body pain are limited. Many strategies to maximize survival have been introduced and still further research has to be conducted.

In the United States, [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is the most frequently diagnosed cancer in men of 65 or older (2010) and the second most common after lung cancer (2005). This disease was more common among blacks (1994-1999). Prostate cancer was also less common before 1974, when the first case was reported. In the US prostate cancer has a 2-fold improvement from 1973 to 1992 in terms of detection. The prognosis is excellent and treatment is very effective when compared to other cancers. Although prostate cancer has been described in horses, it rarely causes death. However, many men are affected by the condition and some, perhaps as many as a fifth, develop benign prostate hyperplasia or prostatitis.

This is the first Australian, national study to show increased mortality in men who had prostate cancer diagnosed in a recent time frame, compared to one in ten who survived until the age of 75. This difference may indicate a need for earlier detection of prostate cancer and better screening of high risk men from a younger age and earlier diagnosis.

Patient and family support can help men understand the implications of test results and promote proactive care. Most men prefer less aggressive form of treatment after receiving results.

This estimate of prostate cancer cases per year in the US was calculated from case reports in a variety of settings. The data supporting this analysis are uncertain and have to be considered for general implementation. The estimates given in this paper should not be used for public policy purposes or as a basis for a health care decision in the case of diagnosis of prostate cancer, but should be considered for epidemiological and market analysis purposes.

The combination of palbociclib plus abiraterone or androgen deprivation therapy has been shown to possess superior response rates, progression-free survival, and progression-free survival compared with either agent as monotherapy. The benefit of this combination relative to abiraterone plus androgen deprivation therapy is particularly pronounced for patients with advanced prostate cancer. In accordance with its FDA approval label, this combination is recommended in patients for whom hormonal ablation therapy is considered following a negative transrectal ultrasound. Furthermore, the combination of abiraterone monotherapy and pembrolizumab is superior to both agents as monotherapy. These differences were found in this study even when accounting for stratification at baseline based on age.

The present data do not support the hypothesis that PSC is an autosomal dominant condition. Furthermore, the present results do not support the concept that PSC is inherited from an unidentified mutation on chromosome 8p11, particularly since no obvious candidate genes for this disease have been identified or implicated thus far.

Findings from a recent study suggests that there is likely to be a significant proportion of men being denied a potentially curative treatment alternative because of low rates of recruitment. Furthermore, the proportion with acceptable outcomes may be far less than previously reported. As more centers begin to initiate clinical trials in this disease, we expect these results to become a real impediment to undertaking prostate cancer research in the UK.

There was no significant relationship between the type of treatment and the rate of metastasis. Patients with Gleason 7 disease appear to have metastasis in roughly equal numbers in both groups, suggesting that the rate of metastatic dissemination is high to begin with.

Commonly reported side effects of palbociclib were mostly mild to moderate and the most common were acne, dry skin, back pain, and constipation, which improved in the majority of patients with palbociclib treatment.